MannKind reported $279.03M in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Adma Biologics USD 399.56M 68.15M Jun/2025
Dynavax Technologies USD 785.71M 30.26M Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Halozyme Therapeutics USD 1.12B 139.35M Jun/2025
Insmed USD 2.08B 678.89M Jun/2025
MacroGenics USD 204.94M 12.55M Jun/2025
MannKind USD 279.03M 5.29M Jun/2025
Merck USD 37.07B 1.56B Jun/2025
Novo Nordisk DKK 174.4B 20.76B Mar/2025
Pfizer USD 43.7B 2.16B Jun/2025
Sanofi 37.02B 7B Jun/2025
Xencor USD 513.15M 8.12M Jun/2025